Ceftobripole: Experience in staphylococcal bacteremia.

Related Articles

Ceftobripole: Experience in staphylococcal bacteremia.

Rev Esp Quimioter. 2019 Sep;32 Suppl 3:24-28

Authors: Soriano A, Morata L

Abstract
Ceftobiprole is a new cephalosporin with an extended spectrum activity against the majority of microorganisms isolated in bacteremia including methicillin-susceptible (MSSA) and -resistant S. aureus (MRSA). This antibiotic has demonstrated a potent activity against MRSA in animal models of endocarditis in monotherapy but particularly in combination with daptomycin, suggesting that this combination could be a future option to improve the outcome of staphylococcal endovascular infections. In addition, the extended-spectrum ceftobiprole activity, including coagulase-negative staphylococci, Enterococcus faecalis, Enterobacteriaceae and Pseudomonas aeruginosa represents an advantage for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as in catheter-related bacteremia.

PMID: 31364338 [PubMed - in process]